Key Details
Price
$3.64Annual ROE
-139.14%Beta
-0.29Events Calendar
Next earnings date:
May 15, 2025Recent quarterly earnings:
Jan 3, 2025Recent annual earnings:
Mar 16, 2017Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 9, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Titan Pharmaceuticals , Inc. ( Nasdaq : TTNP ), relating to its proposed merger with BSKE Ltd. Under the terms of the agreement, Titan shareholders are expected to own approximately 13.3% of the combined company.
NEW YORK , Sept. 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd. Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and KE Sdn. Bhd. is fair to Titan shareholders. Upon closing of the proposed transaction, Titan shareholders expect to own approximately 13.3% of the combined company. Halper Sadeh encourages Titan shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sade.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan's board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Titan will be combined with KE in a “reverse merger” transaction consisting of two steps:
FAQ
- What is the ticker symbol for Titan Pharmaceuticals?
- Does Titan Pharmaceuticals pay dividends?
- What sector is Titan Pharmaceuticals in?
- What industry is Titan Pharmaceuticals in?
- What country is Titan Pharmaceuticals based in?
- When did Titan Pharmaceuticals go public?
- Is Titan Pharmaceuticals in the S&P 500?
- Is Titan Pharmaceuticals in the NASDAQ 100?
- Is Titan Pharmaceuticals in the Dow Jones?
- When was Titan Pharmaceuticals's last earnings report?
- When does Titan Pharmaceuticals report earnings?
- Should I buy Titan Pharmaceuticals stock now?